Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal
mortality and morbidity The only effective treatment is delivery, which leads to significant
neonatal morbidity and mortality if carried out preterm, especially when the disease occurs
early in pregnancy. Vascular endothelial dysfunction and immunological impairment are
associated with preeclampsia. To date, there is no effective or optimal therapeutic approach
for these conditions. Hydroxychloroquine has endothelial protective action via ant diabetic,
lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is
an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed
for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus
erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic
histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve
placental function in pregnancies associated with heightened inflammation.